How Long Has Zepbound Been on the Market?
Zepbound (tirzepatide) gained its first FDA approval for chronic weight management on November 8, 2023, giving patients a new, dual-incretin option alongside GLP-1-only drugs. Since then, its label has already expanded, and insurers are slowly updating coverage.
Zepbound has been on the U.S. market since early December 2023, a few weeks after the FDA cleared it for chronic weight management on November 8, 2023. That makes it a relative newcomer compared with GLP-1 medicines approved more than five years ago, yet it already has millions of prescriptions written and a growing post-marketing safety record. In 2024 the FDA added obstructive sleep apnea as a second indication, further cementing its place in obesity care.
- Zepbound received its first FDA approval for adults with obesity or overweight and at least one weight-related condition on November 8, 2023 (fda.gov).
- Commercial shipping to U.S. pharmacies began in the week of December 4, 2023, so patients have had access for just under three years.
- The active ingredient, tirzepatide, was previously approved under the brand Mounjaro for type 2 diabetes in May 2022.
- In December 2024, the FDA approved Zepbound to improve weight-related outcomes in adults with moderate to severe obstructive sleep apnea who are unable or unwilling to use CPAP (fda.gov).
- Across SURMOUNT-1 and SURMOUNT-2 trials, up to 57 percent of participants lost at least 20 percent of body weight at 72 weeks (fda.gov).
What Zepbound Is
Zepbound is the brand name for tirzepatide when prescribed for weight management. Tirzepatide is a once-weekly injectable peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Dual-receptor activation helps reduce appetite, slow gastric emptying, and improve glucose control, leading to clinically meaningful weight loss. The formulation and dosage strengths (2.5 mg to 15 mg) are identical to those used in Mounjaro for diabetes, but the pen label, indication, and National Drug Code are distinct.
Exactly How Long Zepbound Has Been on the Market
Zepbound has been on pharmacy shelves for 34 months as of October 2026. The drug launched commercially during the week of December 4, 2023, after Eli Lilly completed manufacturing scale-up and wholesale distribution. That means prescribers and patients have had nearly three full calendar years of experience with tirzepatide specifically for weight management.
| Event | Date | Time on Market (to Oct 2026) |
|---|---|---|
| FDA approval for weight management | Nov 8 2023 | 2 years 11 months |
| First shipments to wholesalers | Dec 1 2023 | 2 years 10 months |
| Pharmacy dispensing begins | Week of Dec 4 2023 | 2 years 10 months |
| OSA indication added | Dec 22 2024 | 1 year 10 months |
Key Development and Approval Milestones
Zepbound’s journey from discovery to FDA approval spans more than a decade. Below is a snapshot of the most important milestones.
| Year | Milestone | Why It Matters |
|---|---|---|
| 2012 | Tirzepatide molecule first reported in preclinical papers | Identified as the first GIP/GLP-1 “twincretin.” |
| 2018 | SURPASS phase 3 diabetes trials begin | Established safety profile in metabolic disease. |
| May 2022 | FDA approves tirzepatide as Mounjaro for type 2 diabetes | Gave prescribers first hands-on experience. |
| 2021-2023 | SURMOUNT-1 and -2 obesity trials meet primary endpoints | Demonstrated average 15 percent to 21 percent weight loss. |
| Nov 8 2023 | FDA approves Zepbound for weight management | First dual-incretin cleared for chronic obesity treatment. |
| Dec 22 2024 | FDA adds obstructive sleep apnea indication | First drug therapy approved to improve OSA outcomes via weight loss. |
How Zepbound’s Safety Record Looks So Far
The first three years of post-marketing data have not revealed any new safety signals beyond those seen in clinical trials. Common side effects are gastrointestinal and typically lessen after the dose-escalation period. Below are the most frequently reported adverse events in the SURMOUNT trials, which mirror real-world reports collected through the FDA Adverse Event Reporting System.
| Adverse event | Incidence at 15 mg | Placebo incidence |
|---|---|---|
| Nausea | 31 % | 9 % |
| Diarrhea | 23 % | 9 % |
| Constipation | 17 % | 6 % |
| Vomiting | 12 % | 4 % |
| Dizziness | 7 % | 3 % |
Thyroid C-cell tumor warning: Like all GLP-1-receptor agonists, tirzepatide carries a boxed warning for thyroid C-cell tumors. The risk is theoretical based on rodent studies, and no case of medullary thyroid carcinoma has been confirmed in humans to date.
Current FDA-Approved Uses for Zepbound
Zepbound now has two on-label uses.
- Chronic weight management: Adults with a body-mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity such as hypertension or dyslipidemia.
- Weight-related outcomes in obstructive sleep apnea: Adults with moderate to severe OSA who cannot tolerate or decline positive-airway-pressure therapy. The drug is intended as an adjunct to lifestyle intervention, not a replacement for CPAP if it is tolerated.
The dosing schedule remains the same for both indications: start at 2.5 mg weekly and escalate every four weeks to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg as tolerated (DailyMed).
Insurance Coverage and Access Trends
Coverage for Zepbound has expanded steadily since launch but still varies by plan. Many commercial insurers added it to formulary tiers in 2024, often requiring prior authorization similar to other GLP-1 drugs. For example, Anthem listed Zepbound as a preferred brand in its national drug list starting January 2025 (Anthem Zepbound coverage guide). Medicare Part D coverage remains rare, although CMS signaled that individual Advantage plans may opt in.
Patients paying cash can use LillyDirect for $1,060 per 4-pen carton, which is the same wholesale acquisition cost across all strengths (lillydirect.com). Savings cards can reduce copays to as low as $25 for eligible commercially insured patients.
⚠️ Prior authorization hurdles
Plans often require documented lifestyle-modification efforts and a BMI calculation in the past 12 months. If your prescription was denied, see our step-by-step guide on how to get Zepbound covered by insurance.
Alternatives if You Cannot Access Treatment
If insurance barriers, cost, or supply constraints make brand-name therapy difficult, you have other avenues to discuss with your provider. One option is a compounded dual-incretin program.
The Rx.com weight loss program offers compounded tirzepatide from $149 per month on a 12-month plan. The price includes the online medical visit, medication at any approved dose, and shipping. Compounded tirzepatide is not FDA-approved and is prepared by a 503A pharmacy for an individual prescription.
Other brand-name GLP-1 drugs, such as Wegovy or Ozempic, are also options but may face similar coverage challenges. Discuss the pros and cons with your clinician.
Is now the right time to start Zepbound?
Check the column that fits your situation:
✅ Good candidate
- BMI ≥ 30 kg/m² or ≥ 27 kg/m² with a comorbidity
- Have tried lifestyle changes for at least 6 months
- No personal or family history of medullary thyroid carcinoma
- eGFR above 30 mL/min, normal liver enzymes
- Not pregnant or breastfeeding
🏥 Talk to a doctor first
- History of pancreatitis or gallbladder disease
- Taking insulin or sulfonylureas and prone to hypoglycemia
- Severe GI disease such as gastroparesis
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Planning pregnancy within the next 3 months
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following:
- Severe abdominal pain: could signal pancreatitis.
- Persistent vomiting or inability to keep liquids down: risk of dehydration and electrolyte imbalance.
- Yellowing of the skin or eyes: possible gallbladder or liver injury.
- Difficulty swallowing or neck swelling: may indicate thyroid issues.
- Rapid heartbeat or fainting: could be severe hypoglycemia, especially with other diabetes drugs.
- Signs of allergic reaction: rash, itching, swelling of face or throat.
- Sudden vision changes: rare but serious diabetic retinopathy complications.
Scientific References
Frequently Asked Questions
How long did FDA review take for Zepbound?
The FDA accepted Lilly’s supplemental New Drug Application on May 18 2023 and approved it on November 8 2023, a six-month review under the Prescription Drug User Fee Act.
Is Zepbound the same drug as Mounjaro?
Yes. Both brands contain tirzepatide in identical doses and pens. The difference is the approved indication and product labeling: Mounjaro for type 2 diabetes, Zepbound for weight management and obstructive sleep apnea.
Can I switch from Mounjaro to Zepbound without starting over at 2.5 mg?
If you are already tolerating a higher tirzepatide dose, your provider can usually write the Zepbound prescription at the same dose. Insurance rules may still require documentation.
Will Medicare cover Zepbound in 2026?
Traditional Medicare does not yet cover any obesity drugs, but some Medicare Advantage plans have begun adding coverage. Check your plan’s 2026 formulary.
Does Zepbound need to be refrigerated?
Yes. Unopened pens should be stored in the refrigerator at 36 °F to 46 °F. Pens may be kept at room temperature (up to 86 °F) for a total of 21 days if needed.
How long can I stay on Zepbound?
The FDA labels it for chronic use. Studies show continued benefit up to two years, and ongoing extension trials will clarify longer-term outcomes.
What happens if I miss a weekly dose?
You can take the missed dose within four days of the scheduled date. If more than four days have passed, skip it and resume your usual schedule the next week.
